http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109806250-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate | 2019-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109806250-B |
| titleOfInvention | Application of pharmaceutical composition containing hydroxyurea |
| abstract | The invention provides application of a pharmaceutical composition containing hydroxyurea, which is used for preparing a medicament for preventing and/or treating atherosclerosis by using the hydroxyurea or pharmaceutically acceptable salts thereof. The experimental results show that: after the combination of hydroxyurea, aspirin and clopidogrel hydrogen sulfate is orally taken, the aortic intimal fat and the chyle lesion area are obviously reduced, the drug effect on atherosclerosis is very obvious (the plaque inhibition degree is 85 percent), the concentrations of glucose, triglyceride, total cholesterol and low-density lipoprotein cholesterol in blood are reduced, and the glycolipid metabolic disorder is obviously improved; after the combination of hydroxyurea, aspirin, clopidogrel hydrogen sulfate and atorvastatin calcium is orally taken, the aortic intimal fat and the chylomike lesion area are further obviously reduced and the atherosclerosis is basically cured (the plaque inhibition degree is 91%). The drug combination at the dosage has outstanding therapeutic effect in preventing and/or treating atherosclerosis. |
| priorityDate | 2019-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 102.